Companies in #Liver Fibrosis
Found 2 companies operating in this sector.
Gyre Therapeutics is a commercial-stage biopharmaceutical company developing small-molecule therapies for organ fibrosis and inflammatory disease, operating in both the United States and China. Through its majority-owned subsidiary Gyre Pharmaceuticals it markets ETUARY (pirfenidone capsule), the first approved treatment for idiopathic pulmonary fibrosis in China, and is advancing F351 (hydronidone) — a structurally modified pirfenidone derivative targeting TGF-beta1 signalling — for chronic hepatitis B-associated liver fibrosis in China, where the NDA was accepted with priority review in 2026, and for MASH-associated liver fibrosis in the United States. A May 2026 all-stock acquisition of Cullgen added a targeted protein degrader and degrader-antibody conjugate discovery platform. The company is headquartered in San Diego and majority-owned by GNI USA.
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company that developed and commercialized Rezdiffra (resmetirom), the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-severe liver fibrosis. The company is now pursuing expanded indications and next-generation oral small-molecule therapeutics for liver and metabolic diseases.